Differential regulation of estrogen receptor a expression in breast cancer cells by metastasis-associated protein 1

Cancer Research

Volumn 74, Issue 5, 2014, Pages 1484-1494

  Kang, Hyun Jin ^a   Lee, Min Ho ^a   Kang, Hae Lim ^a   Kim, Sung Hye ^a   Ahn, Jung Ranh ^a   Na, Hyelin ^a   Na, Tae Young ^a   Kim, Yo Na ^a   Seong, Je Kyung ^a   Lee, Mi Ock ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; ESTROGEN RECEPTOR ALPHA; HISTONE DEACETYLASE 2; INTERFERON GAMMA INDUCIBLE PROTEIN 16; MESSENGER RNA; METASTASIS ASSOCIATED PROTEIN 1; OLIGONUCLEOTIDE; ONCOPROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2 GAMMA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; TRANSCRIPTION REGULATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NUCLEAR PROTEINS; PHOSPHOPROTEINS; REPRESSOR PROTEINS; TAMOXIFEN; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION, GENETIC;

EID: 84896537393     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2020     Document Type: Article

References (47)

1. Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor transcription and transactivation: estrogen receptor a and estrogen receptor b: regulation by selective estrogen modulators and importance in breast cancer. Breast Cancer Res 2000;2:335-44.
2. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen receptors; how do they signal and what are their targets. Physiol Rev 2007;87:905-31.
3. Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S. Impact of metastasic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005;90:65-70.
4. Knight WA, Livingston RB, Gregory EJ, McGuire WL. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 1977;7:4669-71.
5. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 2004;96:1311-21.
6. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, et al. Estrogen receptor a (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007;39:655-60.
7. Iwase H, Greenman JM, Barnes DM, Bobrow L, Hodgson S, Mathew CG. Loss of heterozygosity of the oestrogen receptor gene in breast cancer. Br J Cancer 1995;71:448-50.
8. Herynk MH, Fuqua SA. Estrogen receptor mutation in human disease. Endocr Rev 2004;25:869-98.
9. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 1994;54:2552-5.
10. Pinzone JJ, Stevenson H, Strobl JS, Berg PE. Molecular and cellular determinants of estrogen receptor a expression. Mol Cell Biol 2004; 24:4605-12
11. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-A by DNA methyltransferase and histone deacetylase I inhibition in human ER-A-negative breast cancer cells. Cancer Res 2001;61: 7025-29.
12. Sharma D, Saxena NK, Davidson NE, Vertino PM. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res 2006;66:6370-78.
13. Fan J, Yin WJ, Lu JS, Wang L, Wu J, Wu FY, et al. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol 2008;134:883-90
14. Macaluso M, Cinti C, Russo G, Russo A, Giordano A. pRb2/p130-E2F4/5- HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-Alpha in breast cancer. Oncogene 2003;22: 3511-7.
15. Vesuna F, Lisok A, Kimble B, Domek J, Kato Y, van der Groep P, et al. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-A. Oncogene 2012;31:3223-34.
16. Toh Y, Nicolson GL. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis 2009;26:215-27.
17. Toh Y, Pencil SD, Nicolson GL. A novel candidate Metastasis-Associated gene, mta1, differentially expressed in highly metastatic mammart adenocarcinoma cell lines. cDNA cloning, expression, and protein analysis. J Bio Chem 1994;269:22958-63.
18. Martin MD, Fischbach K, Osborne CK, Mohsin SK, Allred DC, O'Connell P. Loss of heterozygosity events impeding breast cancer metastasis contains the MTA1 gene. Cancer Res 2001;61:3578-80.
19. Jang KS, Paik SS, Chung H, Oh YH, Kong G. MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Sci 2006;97:374-9.
20. Manavathi B, Singh K, Kumar R. MTA family of coregulators in nuclear receptor biology and pathology. Nucl Recept Signal 2007;5:e010.
21. Gururaj AE, Holm C, Landberg G, Kumar R. Breast cancer-Amplified sequence 3, a target of metastasis-Associated protein 1, contributes to tamoxifen resistance in premenopausal patients with breast cancer. Cell Cycle 2006;5:1407-10.
22. Molli PR, Singh RR, Lee SW, Kumar R. MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene. Oncogene 2008;27: 1971-80.
23. Jiang Q, Zhang H, Zhang P. ShRNA-mediated gene silencing of MTA1 influenced on protein expression of ER alpha, MMP-9, cyclin D1 and invasiveness, proliferation in breast cancer cell lines MDA-MB-231 and MCF-7 in vitro. J Exp Clin Cancer Res 2011;30:60.
24. Lee MH, Na H, Kim EJ, Lee HW, Lee MO. Poly(ADP-ribosyl)ation of p53 induces gene-specific transcriptional repression of MTA1. Oncogene 2012;31:5099-107.
25. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
26. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-41.
27. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007;13:3207-14.
28. Waddell N, Cocciardi S, Johnson J, Healey S, Marsh A, Riley J, et al. Gene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay. J Pathol 2010;221:452-61.
29. Kos M, Reid G, Denger S, Gannon F. Mini review:genomic organization of the human ERa gene promoter region. Mol Endocrinol 2001;15: 2057-63.
30. Tang Z, Treilleux I, Brown M.Atranscriptional enhancer required for the differential expression of the human estrogen receptor in breast cancers. Mol Cell Biol 1997;17:1274-80.
31. Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE. Release of methyl CpG binding proteins and histone deacetylase 1 from the estrogen receptor a (ER) promoter upon reactivation in ERnegative human breast cancer cells. Mol Endocrinol 2005;19: 1740-51.
32. Woodfield GW, Hitchler MJ, Chen Y, Domann FE, Weigel RJ. Interaction of TFAP2C with the estrogen receptor-A promoter is controlled by chromatin structure. Clin Cancer Res 2009;15:3672-9.
33. Woodfield GW, Horan AD, Chen Y, Weigel RJ. TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling. Cancer Res 2007;67:8439-43.
34. Reid G, Metivier R, Lin CY, Denger S, Ibberson D, Ivacevic T, et al. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 2005;24: 4894-907.
35. Fortunati N, Bertino S, Costantino L, De Bortoli M, Compagnone A, Bandino A, et al. Valproic acid restores ERa and antiestrogen sensitivity to ERa-negative breast cancer cells. Mol Cell Endocrinol 2010;314:17-22.
36. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004;64:1079-86.
37. Asefa B, Klarmann KD, Copeland NG, Gilbert DJ, Jenkins NA, Keller JR. The interferon-inducible p200 family of proteins: a perspective on their roles in cell cycle regulation and differentiation. Blood Cells Mol Dis 2004;32:155-67.
38. Chen LC, Dollbaum C, Smith HS. Loss of heterozygosity on chromosome 1q in human breast cancer. Proc Natl Acad Sci U S A 1989; 86:7204-7.
39. Harvell DM, Richer JK, Allred DC, Sartorius CA, Horwitz KB. Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Endocrinology 2006; 147:700-13.
40. Alimirah F, Chen J, Xin H, Choubey D. Androgen receptor auto-regulates its expression by a negative feedback loop through upregulation of IFI16 protein. FEBS Lett 2006;580: 1659-64.
41. Hickey TE, Robinson JL, Carroll JS, Tilley WD. Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol 2012;26:1252-67.
42. McPherson LA, Baichwal VR, Weigel RJ. Identification of ERF-1 as a member of the AP2 transcription factor family. Proc Natl Acad Sci USA 1997;94:4342-7.
43. Reddy SD, Pakala SB, Molli PR, Sahni N, KaranamNK, Mudvari P, et al. Metastasis-Associated protein 1/histone deacetylase 4-nucleosome remodeling and deacetylase complex regulates phosphatase and tensin homolog gene expression and function. J Biol Chem 2012;287: 27843-50.
44. Woodfield GW, Chen Y, Bair TB, Domann FE, Weigel RJ. Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells. Genes Chromosomes Cancer 2010;49:948-62.
45. Ghanta KS, Li DQ, Eswaran J, Kumar R. Gene profiling of MTA1 identifies novel gene targets and functions. PLoS One 2011;6: e17135.
46. Cicatiello L, Mutarelli M, Grober OM, Paris O, Ferraro L, RavoM , et al. Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am J Pathol 2010;176:2113-30.
47. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapyresistant breast cancer. Br J Cancer 2011;104:1828-35.